The Claim
Treatment with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes is not associated with an increased risk of major cardiovascular events compared to active antidiabetic therapies, with an overall odds ratio of 0.74 (95% CI 0.50–1.08).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes, glucagon-like peptide-1 receptor agonists do not increase the risk of major cardiovascular events compared to other diabetes medications.
See the scientific wording
In adults with type 2 diabetes, treatment with glucagon-like peptide-1 receptor agonists is not associated with an increased risk of major cardiovascular events compared to active antidiabetic therapies, with an overall odds ratio of 0.74 (95% CI 0.50–1.08), suggesting no net harm to cardiovascular health.
GLP-1 receptor agonists improve the health of blood vessel linings and lower chronic inflammation in the body, which prevents damage that can lead to heart attacks and strokes.
What the research says
1 studyFor people with type 2 diabetes, this study found that GLP-1 drugs don’t cause more heart attacks or strokes than other common diabetes medicines like insulin or sulfonylureas. So, they’re just as safe for the heart.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.